Company Cash on Hand: Sionna Therapeutics Inc (SION)

Sionna Therapeutics Inc (SION) relies on external contractors' facilities for the production of cystic fibrosis therapies. The current level of cash reserves, fixed at 0.22, illustrates the startup's liquidity. The company is scaling its line of small-molecule agents to transition to Phase 2 trials, while simultaneously implementing water and air purification systems to minimize the laboratories' environmental footprint.
Metric breakdowns and analytics for Sionna Therapeutics, Inc. (SION)

Cash volume reflects immediate liquidity through the amount of cash and cash equivalents on the balance sheet, allowing an investor to assess the financial cushion. By analyzing changes in cash levels, one can determine the ability of Sionna Therapeutics Inc (SION) to fund costly small-molecule clinical trials for cystic fibrosis without the urgent need to raise external capital.